The company, a majority-owned affiliate of Ionis Pharmaceuticals, announced Sept. 23 the departures of CEO Paula Soteropoulos, President Sarah Boyce and COO Jeff Goldberg, effective immediately.
Danueb McDevitt, PhD, the chief business officer of Ionis was named interim CEO. The company didn’t announce interim replacements for the president or COO.
The leadership shakeup comes a year after the company launched its first FDA-approved drug, Tegsedi, a treatment for a rare disease called hereditary transthyretin amyloidosis, according to STAT.
More articles on pharmacy:
Carcinogen concerns prompt Sandoz to halt global distribution of heartburn drug
DEA raids some West Coast Kaiser Permanente pharmacies
California biotech files for bankruptcy
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.